---
document_datetime: 2025-12-29 14:35:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/grastofil.html
document_name: grastofil.html
version: success
processing_time: 0.1039131
conversion_datetime: 2025-12-31 01:57:09.81992
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Grastofil

[RSS](/en/individual-human-medicine.xml/67047)

##### Withdrawn

This medicine's authorisation has been withdrawn

filgrastim Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Grastofil](#news-on)
- [Related content](#related-content-862)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 13 January 2025, the European Commission withdrew the marketing authorisation for Grastofil (filgrastim) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Accord Healthcare S.L.U., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Grastofil was granted marketing authorisation in the EU on 18 October 2013 for the treatment of neutropenia. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2018.

Grastofil is an identical product to Neupogen, which is authorised in the EU to treat neutropenia.

The European public assessment report (EPAR) for Grastofil will be updated to indicate that the marketing authorisation is no longer valid.

Grastofil : EPAR - Medicine overview

Reference Number: EMA/569200/2018

English (EN) (95.79 KB - PDF)

**First published:** 12/11/2018

[View](/en/documents/overview/grastofil-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-518)

български (BG) (127.87 KB - PDF)

**First published:**

12/11/2018

[View](/bg/documents/overview/grastofil-epar-medicine-overview_bg.pdf)

español (ES) (95.54 KB - PDF)

**First published:**

12/11/2018

[View](/es/documents/overview/grastofil-epar-medicine-overview_es.pdf)

čeština (CS) (121.01 KB - PDF)

**First published:**

12/11/2018

[View](/cs/documents/overview/grastofil-epar-medicine-overview_cs.pdf)

dansk (DA) (93.57 KB - PDF)

**First published:**

12/11/2018

[View](/da/documents/overview/grastofil-epar-medicine-overview_da.pdf)

Deutsch (DE) (96.7 KB - PDF)

**First published:**

12/11/2018

[View](/de/documents/overview/grastofil-epar-medicine-overview_de.pdf)

eesti keel (ET) (91.65 KB - PDF)

**First published:**

12/11/2018

[View](/et/documents/overview/grastofil-epar-medicine-overview_et.pdf)

ελληνικά (EL) (135.06 KB - PDF)

**First published:**

12/11/2018

[View](/el/documents/overview/grastofil-epar-medicine-overview_el.pdf)

français (FR) (96.26 KB - PDF)

**First published:**

12/11/2018

[View](/fr/documents/overview/grastofil-epar-medicine-overview_fr.pdf)

hrvatski (HR) (116.14 KB - PDF)

**First published:**

12/11/2018

[View](/hr/documents/overview/grastofil-epar-medicine-overview_hr.pdf)

italiano (IT) (94.7 KB - PDF)

**First published:**

12/11/2018

[View](/it/documents/overview/grastofil-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (117.82 KB - PDF)

**First published:**

12/11/2018

[View](/lv/documents/overview/grastofil-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (118.44 KB - PDF)

**First published:**

12/11/2018

[View](/lt/documents/overview/grastofil-epar-medicine-overview_lt.pdf)

magyar (HU) (116.84 KB - PDF)

**First published:**

12/11/2018

[View](/hu/documents/overview/grastofil-epar-medicine-overview_hu.pdf)

Malti (MT) (121.34 KB - PDF)

**First published:**

12/11/2018

[View](/mt/documents/overview/grastofil-epar-medicine-overview_mt.pdf)

Nederlands (NL) (95.03 KB - PDF)

**First published:**

12/11/2018

[View](/nl/documents/overview/grastofil-epar-medicine-overview_nl.pdf)

polski (PL) (121.29 KB - PDF)

**First published:**

12/11/2018

[View](/pl/documents/overview/grastofil-epar-medicine-overview_pl.pdf)

português (PT) (95.62 KB - PDF)

**First published:**

12/11/2018

[View](/pt/documents/overview/grastofil-epar-medicine-overview_pt.pdf)

română (RO) (118.26 KB - PDF)

**First published:**

12/11/2018

[View](/ro/documents/overview/grastofil-epar-medicine-overview_ro.pdf)

slovenčina (SK) (119.08 KB - PDF)

**First published:**

12/11/2018

[View](/sk/documents/overview/grastofil-epar-medicine-overview_sk.pdf)

slovenščina (SL) (113.73 KB - PDF)

**First published:**

12/11/2018

[View](/sl/documents/overview/grastofil-epar-medicine-overview_sl.pdf)

Suomi (FI) (94.57 KB - PDF)

**First published:**

12/11/2018

[View](/fi/documents/overview/grastofil-epar-medicine-overview_fi.pdf)

svenska (SV) (95.01 KB - PDF)

**First published:**

12/11/2018

[View](/sv/documents/overview/grastofil-epar-medicine-overview_sv.pdf)

Grastofil : EPAR - Risk-management-plan summary

English (EN) (198.81 KB - PDF)

**First published:** 29/06/2020

[View](/en/documents/rmp-summary/grastofil-epar-risk-management-plan-summary_en.pdf)

## Product information

Grastofil : EPAR - Product Information

English (EN) (901.31 KB - PDF)

**First published:** 11/11/2013

**Last updated:** 31/08/2023

[View](/en/documents/product-information/grastofil-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-479)

български (BG) (800.17 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/bg/documents/product-information/grastofil-epar-product-information_bg.pdf)

español (ES) (825.42 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/es/documents/product-information/grastofil-epar-product-information_es.pdf)

čeština (CS) (806.34 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/cs/documents/product-information/grastofil-epar-product-information_cs.pdf)

dansk (DA) (881.16 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/da/documents/product-information/grastofil-epar-product-information_da.pdf)

Deutsch (DE) (816.87 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/de/documents/product-information/grastofil-epar-product-information_de.pdf)

eesti keel (ET) (886.91 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/et/documents/product-information/grastofil-epar-product-information_et.pdf)

ελληνικά (EL) (1.01 MB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/el/documents/product-information/grastofil-epar-product-information_el.pdf)

français (FR) (972.95 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/fr/documents/product-information/grastofil-epar-product-information_fr.pdf)

hrvatski (HR) (1.07 MB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/hr/documents/product-information/grastofil-epar-product-information_hr.pdf)

íslenska (IS) (770.68 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/is/documents/product-information/grastofil-epar-product-information_is.pdf)

italiano (IT) (881.97 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/it/documents/product-information/grastofil-epar-product-information_it.pdf)

latviešu valoda (LV) (912.95 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/lv/documents/product-information/grastofil-epar-product-information_lv.pdf)

lietuvių kalba (LT) (917.29 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/lt/documents/product-information/grastofil-epar-product-information_lt.pdf)

magyar (HU) (944.67 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/hu/documents/product-information/grastofil-epar-product-information_hu.pdf)

Malti (MT) (1019.67 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/mt/documents/product-information/grastofil-epar-product-information_mt.pdf)

Nederlands (NL) (880.24 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/nl/documents/product-information/grastofil-epar-product-information_nl.pdf)

norsk (NO) (790.5 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/no/documents/product-information/grastofil-epar-product-information_no.pdf)

polski (PL) (944.66 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/pl/documents/product-information/grastofil-epar-product-information_pl.pdf)

português (PT) (846.53 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/pt/documents/product-information/grastofil-epar-product-information_pt.pdf)

română (RO) (1.03 MB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/ro/documents/product-information/grastofil-epar-product-information_ro.pdf)

slovenčina (SK) (1.06 MB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/sk/documents/product-information/grastofil-epar-product-information_sk.pdf)

slovenščina (SL) (887.96 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/sl/documents/product-information/grastofil-epar-product-information_sl.pdf)

Suomi (FI) (891.86 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/fi/documents/product-information/grastofil-epar-product-information_fi.pdf)

svenska (SV) (747.86 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

31/08/2023

[View](/sv/documents/product-information/grastofil-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0039 22/12/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Grastofil : EPAR - All Authorised presentations

English (EN) (31.03 KB - PDF)

**First published:** 11/11/2013

**Last updated:** 11/11/2013

[View](/en/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-348)

български (BG) (54.14 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/bg/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_bg.pdf)

español (ES) (32.02 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/es/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48.87 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/cs/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (30.99 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/da/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (30.52 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/de/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (30.53 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/et/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (56.07 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/el/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_el.pdf)

français (FR) (30.48 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/fr/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (37.67 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/hr/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (32.11 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/is/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_is.pdf)

italiano (IT) (31.95 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/it/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.13 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/lv/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (47.27 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/lt/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (47.96 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/hu/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (51.14 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/mt/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (31.81 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/nl/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (30.47 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/no/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.18 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/pl/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_pl.pdf)

português (PT) (30.71 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/pt/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_pt.pdf)

română (RO) (51.5 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/ro/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (47.84 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/sk/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (38.74 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/sl/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.27 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/fi/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (32.3 KB - PDF)

**First published:**

11/11/2013

**Last updated:**

11/11/2013

[View](/sv/documents/all-authorised-presentations/grastofil-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Grastofil Active substance filgrastim International non-proprietary name (INN) or common name filgrastim Anatomical therapeutic chemical (ATC) code L03AA02

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

Grastofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.

The safety and efficacy of Grastofil are similar in adults and children receiving cytotoxic chemotherapy.

Grastofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).

In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 10 9 /L, and a history of severe or recurrent infections, long term administration of Grastofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.

Grastofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 10 9 /L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

## Authorisation details

EMA product number EMEA/H/C/002150

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 25/07/2003 Marketing authorisation issued 18/10/2013 Withdrawal of marketing authorisation 13/01/2025 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Grastofil : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (219.71 KB - PDF)

**First published:** 03/01/2014

**Last updated:** 31/08/2023

[View](/en/documents/procedural-steps-after/grastofil-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Grastofil : EPAR - Public assessment report

Adopted

Reference Number: EMEA/CHMP/303037/2013

English (EN) (2.19 MB - PDF)

**First published:** 11/11/2013

**Last updated:** 11/11/2013

[View](/en/documents/assessment-report/grastofil-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Grastofil

Adopted

Reference Number: EMA/CHMP/304525/2013

English (EN) (112.71 KB - PDF)

**First published:** 26/07/2013

**Last updated:** 26/07/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-grastofil_en.pdf)

#### News on Grastofil

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

#### Related content

- [Biosimilar medicines](/en/human-regulatory-overview/biosimilar-medicines-overview)

#### Topics

- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 26/09/2025

## Share this page

[Back to top](#main-content)